Article (Scientific journals)
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent; Lancellotti, Patrizio; Garcia, Monica Tome et al.
2016In Endocrine
Peer Reviewed verified by ORBi
 

Files


Full Text
Vroonen et al 2016 (Cabergoline Echo).pdf
Publisher postprint (425.35 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Cabergoline; Cardiac valve; Echocardiography; Hyperprolactinemia; Prolactinoma
Abstract :
[en] Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
VROONEN, Laurent ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
Lancellotti, Patrizio  ;  Université de Liège > Département des sciences cliniques > Imagerie cardiaque fonctionnelle par échographie
Garcia, Monica Tome
DULGHERU, Raluca Elena ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique des valvulopathies - Echocardiographies - Imagerie
Rubio-Almanza, Mathilde
Maiga, Ibrahima
Magne, Julien
PETROSSIANS, Patrick  ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
Auriemma, Renata ;  Université de Liège - ULiège > Doct. sc. médicales (Bologne)
Daly, Adrian  ;  Université de Liège > Département des sciences cliniques > Endocrinologie
Beckers, Albert ;  Université de Liège > Département des sciences cliniques > Endocrinologie
Language :
English
Title :
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Publication date :
05 October 2016
Journal title :
Endocrine
ISSN :
1355-008X
eISSN :
1559-0100
Publisher :
Springer
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 07 November 2016

Statistics


Number of views
314 (15 by ULiège)
Number of downloads
689 (11 by ULiège)

Scopus citations®
 
25
Scopus citations®
without self-citations
22
OpenCitations
 
21

Bibliography


Similar publications



Contact ORBi